株式会社スコヒアファーマ News Releases

Regarding the Execution of a Global Exclusive License Agreement with Neurocrine Biosciences for Selective MC2R Antagonist SCO-483

Scohia Pharma entered into a global exclusive license agreement with Neurocrine Switzerland GmbH for… · 2026-04-10

Regarding the Execution of a Global Exclusive License Agreement with Neurocrine Biosciences for Selective MC2R Antagonist SCO-483

Scohia Pharma entered into a global exclusive license agreement with Neurocrine Switzerland GmbH for… · 2026-04-10

Scohia Pharma Raises 3 Billion JPY via Third-Party Allotment

Scohia Pharma has raised 3 billion JPY through a third-party allotment of shares. The company, a spi… · 2026-05-28